This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): drospirenone and estradiol
Description: Angeliq is a low-dose combination estradiol (estrogen) and drospirenone (progestogens). Unlike most synthetic progestogens, drospirenone mimics the hormone progesterone, which exerts anti-androgenic and anti-mineralocorticoid effects. Thus, drospirenonecounteracts the water retention, potential weight gain, and increase in blood pressure that estrogen and many synthetic progestins cancause.
Deal Structure: In 2006, Bayer acquired Schering AG.
Pink Sheet Schering AG/Berlex Angeliq second try
Pink Sheet Berlex Angeliq is “approvable”
Additional information available to subscribers only: